New registry aims to uncover heart disease secrets in russia
NCT ID NCT07295613
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is creating a large database of 1400 adults and children with hypertrophic cardiomyopathy (HCM) in Russia. Researchers will track their health over time to learn how the disease progresses and affects daily life. The goal is to improve diagnosis and care for HCM patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 1,400 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2023
- Expected to finish
-
Oct 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
adult and pediatric patients with HCM
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Any age * Signed informed consent form (ICF) for participation in the study, including genetic testing * Meets the criteria for HCM HCM Criteria for Probands ≥ 18 Years Based on ECHO or CMR * End-diastolic LV wall thickness ≥ 15mm in any segment of the LV HCM Criteria for Probands ≥ 18 Years with Arterial Hypertension * 1st degree of AH: The same ECHO/CMR criteria as patients without AH * 2nd and 3rd degrees of AH: * Asymmetric LV hypertrophy: the ratio of septum / LV PW ≥ 1.5 or apical HCM * If asymmetry \< 1.5, the wall thickness must be ≥ 20mm * For all patients with arterial hypertension, the presence of at least one of the following ECG changes is obligatory: * Pathological "dagger" Q wave * T-wave inversion ≥ 3mm in ≥ 2 adjacent leads * Poor R progression / QS / RV1 \> RV2 \< RV3 in V1-V4 HCM Criteria for First-degree Relatives ≥ 18 Years Based on ECHO or CMR and ECG: * End-diastolic LV wall thickness ≥ 13mm in any segment and/or ECG changes in the absence of CAD, such as (at least one of the following): * Quantitative signs of LV hypertrophy\* + repolarization changes * T wave inversions in at least 2 adjacent leads: ≥ 3mm in V3-V6, I, aVL or ≥ 5mm in II, III, aVF * Pathological Q waves (\> 25% of R) in at least 2 adjacent leads: II, III, aVF (in the absence of left anterior hemiblock) or V1-V4, or I, aVL, V5-V6 \*Presence at least one of the following: * Sokolow-Lyon index (S in V1 + R in V5 or V6) \> 35mm * R or S in limb leads ≥ 20mm * S in V1 or V2 ≥ 30mm * R in V5 or V6 ≥ 30mm HCM Criteria for Children and Adolescents \< 18 Years * End-diastolic LV wall thickness in any segment \> 2.5 standard deviations (\> 2.5 z-score) above the norms for the index gender, age and weight (or body surface area) in asymptomatic children/adolescents without a family history of HCM * End-diastolic LV wall thickness in any segment \> 2.0 standard deviations (\> 2.0 z-score) above the norms for the index gender, age and weight (or body surface area) in children/adolescents with a family history of HCM or a positive genetic test Exclusion Criteria: * Uncontrolled arterial hypertension of 2nd - 3rd degree with mild/moderate (\< 20mm) or symmetric LV hypertrophy or a "normal" ECG * Hemodynamically significant congenital or acquired valve heart disease * Established diagnosis of metabolic, infiltrative, endocrine, or other diseases known as "phenocopies of HCM"
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hypertrophic cardiomyopathy (HCM) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
CGMA
Moscow, Russia
-
Central State Medical Academy
Moscow, Moscow Reg, 1213059, Russia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- 3,000 hearts, one goal: mapping how hypertrophic cardiomyopathy unfolds in china
- Heart scan AI could predict sudden cardiac death risk in common heart condition
- Experimental pill aims to ease thick heart muscle symptoms
- Massive HCM database aims to unlock better heart care
- Heart drug swap tested for safer symptom control
- Real-World HCM drug use under the microscope